19-Dec-2025
Cardinal Health Board of Directors Approves Quarterly Dividend
PRNewswire (Tue, 4-Nov 4:45 PM ET)
Cardinal Health completes acquisition of Solaris Health
PRNewswire (Mon, 3-Nov 8:30 AM ET)
Cardinal Health Reports First Quarter Fiscal Year 2026 Results and Raises Outlook
PRNewswire (Thu, 30-Oct 6:45 AM ET)
Cardinal Health to expand pharmaceutical distribution network with new Indianapolis facility
PRNewswire (Tue, 30-Sep 9:07 AM ET)
Cardinal Health to Announce First-Quarter Results for Fiscal Year 2026 on October 30
PRNewswire (Tue, 23-Sep 6:45 AM ET)
CAH Plunges 7.1% on Earnings Day Despite Beating Guidance—Does History Suggest a Rebound Is Ahead?
Market Chameleon (Tue, 12-Aug 8:46 AM ET)
Cardinal Health is one of three leading pharmaceutical wholesalers in the US, engaged in sourcing and distributing of branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. Cardinal, Cencora, and McKesson hold well over 90% of the US pharmaceutical wholesale industry. Cardinal Health also supplies medical-surgical products and equipment to healthcare facilities in North America, Europe, and Asia.
Cardinal Health trades on the NYSE stock market under the symbol CAH.
As of December 19, 2025, CAH stock price climbed to $202.95 with 3,304,459 million shares trading.
CAH has a beta of 0.40, meaning it tends to be less sensitive to market movements. CAH has a correlation of 0.08 to the broad based SPY ETF.
CAH has a market cap of $48.22 billion. This is considered a Large Cap stock.
Last quarter Cardinal Health reported $64 billion in Revenue and $2.55 earnings per share. This beat revenue expectation by $5 billion and exceeded earnings estimates by $.36.
In the last 3 years, CAH traded as high as $214.93 and as low as $68.53.
The top ETF exchange traded funds that CAH belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.
CAH has outperformed the market in the last year with a price return of +75.2% while the SPY ETF gained +18.1%. CAH has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +36.0% and +2.1%, respectively, while the SPY returned +2.8% and -0.5%, respectively.
CAH support price is $196.74 and resistance is $201.46 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CAH shares will trade within this expected range on the day.